SIRT3 and pancreatic neoplasm: In our study, we found that a knockdown of SIRT3 by shRNA in pancreatic cancer cells led to a significant resistant to MRTX1133, whereas overexpression of SIRT3 enhanced the sensitivity of pancreatic cancer cells to MRTX1133 (Fig. S7).